The collaboration with a hospital in the United States where two clinical trials of Cuban vaccines against lung cancer will help to gather new scientific data to increase the products´ value.

According to Dr. Tania Crombet, director of Clinical Researches of the Molecular Immunology Center (CIM, for its abbreviation in Spanish), where both drugs were developed, the trials in the phases I/II will seek to demonstrate the security of the Cuban compounds combined with another molecule recently registered by the United States.

The trials, with around 100 patients each, will prove the interaction with Nivolumab, a second line therapy for patients with recurrent lung cancer, which Cuba does not have access because of the blockade of that country´s government, and also because of the high cost, explained Crombet.

Besides the demonstration of the therapeutic security, the trials can also obtain a better characterization of the expression of the tumor antigens, and a genetic comparison between the primary and the secondary tumors, in order to predict even which patients would respond better to the therapy.

The scientist added that the American team, integrated by researchers of the Roswell Park Cancer Institute in the state of New York, is highly motivated to advance in the collaboration with Cuba, since they have much faith in the possibilities of Cimavax EGF and Nimotuzumab to extend the survival of patients and with quality of life.

Candance S. Johnson, president of the Roswell Park, recently confirmed this in an interview reproduced in the website Cubadebate, where the academy showed itself admired by the creative approach of Cuban products, as they do not directly attack the tumor, they attack the markers which stimulate its growth, and they also strengthen the immunologic system.

In the United States as well as in Cuba, the lung cancer is one of the first causes of death due to cancer, that´s why the American researchers think of a future in which the vaccines will be even preventive, according to the considerations of Johnson.

However, Dr. Crombet specified that the immunotherapy is still a complement of other conventional treatments such as surgery, chemotherapy and radiotherapy, and that the best weapon to fight against cancer is the reduction of the risk factors such as the habit of smoking.

In an encounter with doctors and researchers of Camagüey province that lead the clinical trials of these products and others, the director of CIM presented the results of the institution in 2016, and this year plans. She also evaluated the development of the scientific activity in the territory.

Translated by Linet Acuña Quilez